"Exopolysaccharide is the immune system response modulator in mammals, including humans (Example 3B). The exopolysaccharide is apyrogenic for rabbits when administered intravenously at a dose of no more than 0.050 mcg/kg in a rabbit pyrogenicity test (Example 1D).
"The claimed pharmaceutical composition may comprise pharmaceutically acceptable targeted additives, which may include preservatives, stabilizers, solvents or combinations of them.
"The claimed pharmaceutical composition can have a wide range of pharmacological activity and exhibits, in particular, an effective therapeutic antiviral effect under infection caused by influenza A virus subtype H1N1 (Example 3B, FIG. 9)
"Also claimed is the use of polysaccharide from S. sonnei, phase I bacteria for production of vaccine or pharmaceutical composition. The stated polysaccharide consists of 1-100 repeating disaccharide units of O-[4-amino-2-(N-acetyl)amino-2,4-dideoxy-.beta.-D-galactopyranosyl]-(1.fw- darw.4)-O-[-2-(N-acetyl)amino-2-deoxy-.alpha.-L-altrpyranuronic acid] connected by (1.fwdarw.3) bonds to form a polysaccharide chain, and obtained using S. sonnei bacteria, but without the use of lipopolysaccharides as its source.
"This polysaccharide is an exopolysaccharide, or capsular polysaccharide, secreted into the cultural medium by S. sonnei, phase I bacteria. The native exopolysaccharide includes a non-toxic lipid component, presented by non hydroxylated fatty acids from 16-18 carbon atoms in the molecule (FIG. 4). Its fatty acid content is less than 0.01% (w/w). Additionally, independently from the method of preparation with use S. sonnei bacteria, the polysaccharide does not include elements of the structure of LPS core domain (FIG. 4).
"Exopolysaccharide can be prepared by any method, including genetic engineering, using the genome of S. sonnei bacteria. Preferably the exopolysaccharide is produced using S. sonnei bacteria by a method comprising: (a) producing bacterial culture in liquid phase; (b) separating the liquid phase from bacterial cells; © isolating the polysaccharide from liquid phase. Meanwhile, in order to avoid destroying the cell walls and LPS entry into the liquid phase, separation it from the bacterial cells is advisable to carry out under conditions for maintain the nativity of bacterial cells. Isolating the polysaccharide from the liquid phase can be carried out by a method comprising: (i) removing proteins and nucleic acids from the liquid phase; (ii) ultrafiltration and (iii) dialysis of obtained solution.
"Obtained using the above method exopolysaccharide contains no more than 1% (w/w) of protein and 2% (w/w) of nucleic acid. The molecular weight of the polysaccharide, which is measured by gel filtration, is varied from 0.4 to 400 kDa. The main fraction of the polysaccharide is a biopolymer with molecular weight over 80 kDa (FIG. 5B).
"Exopolysaccharide is immunogenic and causes mucosal protection from S. sonnei shigellosis by inducing synthesis of a specific antibodies against S. sonnei, phase I bacteria in mammalian organisms, including humans (Example 1C, FIG. 6; Examples 2D, 2F). Additionally, the exopolysaccharide is also a modulator of immune system response in mammals, including humans (Example 3B). The exopolysaccharide is apyrogenic for rabbits when administered intravenously at a dose of no more than 0.050 mcg/kg in a rabbit pyrogenicity test (Example 1D).
"The exopolysaccharide is apyrogenic for rabbits at a dose of no more than 0.050 mg/kg in a pyrogenicity test in rabbits when administered intravenously (Example 1D). The produced vaccine and pharmaceutical composition are intended for parenteral, oral, rectal, intra-vaginal, transdermal, sublingual and aerosol administration to mammals, including humans.
Most Popular Stories
- NSA Defends Global Cellphone Tracking Legality
- Top Websites for U.S. Hispanics
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- Apple Wants Samsung to Pay $22M for Patent Dispute Legal Bills
- Starbucks Gets Grinchy; No Gingerbread Lattes for Tampa Customers
- Apple Paid Its Lawyers More Than $60MM to Defeat Samsung in Court
- Jobs Report Brings Cheer As Unemployment Drops to Five-year Low
- Economic Bright Spots Not a Sure Boost for President Obama
- US Consumer Borrowing Rose $18.2B in Oct.